I-Corps: Nano Drug Enabled Cancer Therapy

I-Corps项目更广泛的影响/商业潜力是开发一个平台来了解纳米颗粒的毒理学特性，并最终允许开发更好的乳腺癌治疗策略。这项工作将为进一步了解纳米颗粒在特定癌症类型中的应用以及了解致癌转化奠定基础。根据体内模型中细胞对这些配方的反应，这些研究具有转化潜力，并可能为临床试验奠定基础。在未来的研究中，我们建议添加针对不同途径或同一途径的不同成分的药物以及其他癌症特征，如代谢重编程和免疫。此外，在我们的纳米平台中加入与恶性肿瘤相关的表观遗传变化抑制剂将有更大的商业应用。该项目将进行客户发现，以寻求产品的市场契合度，并进一步支持制定安全有效的癌症治疗应用策略。这个I-Corps项目是基于开发新的纳米颗粒和抗原，在癌细胞上高度表达，以传递药物来抑制细胞增殖的途径。该平台可用于治疗其他类型的癌症，例如胰腺癌。纳米颗粒对靶向EpCAM或Her2或两者的aunr / ag -雷帕霉素产生强大的协同凋亡反应。该平台还使用fda批准的雷帕霉素，开发纳米配方，减少毒副作用。未来的研究将增加针对不同途径或同一途径的不同成分的药物，以及其他癌症特征，如代谢重编程和免疫。此外，结合与恶性肿瘤相关的表观遗传变化的抑制剂将有很大的商业应用。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is the development of a platform to understanding of the toxicological properties of nanoparticles and ultimately allow for the development of better therapeutic strategies for breast cancer treatment. This work will form a basis for further understanding of the use of nanoparticles in targeting specific cancer types and learn about oncogenic transformation. Depending upon cell response to these formulations in in vivo models, these studies have translational potential and might form basis for clinical trial. For future studies, we propose to add drugs that target different pathways or different components of the same pathway and other hallmarks of cancer such as metabolic reprogramming and immunity. Additionally, incorporating inhibitors of epigenetic changes linked to malignancies in our nano-platform would be of greater commercial application. This project will conduct customer discovery to seek product market fit and further support the development of strategies for safe and effective cancer treatment applications.This I-Corps project is based on the development of novel nanoparticles and antigens highly expressed on cancer cells to deliver drugs to inhibit cell proliferative pathway. This platform can be adapted to treat other cancer types, e.g., pancreatic cancer. The nanoparticles create a robust, synergistic apoptotic response to AuNRs/Ag-rapamycin targeting EpCAM or Her2, or both. The platform also uses FDA-approved, rapamycin, developing nano-formulations that reduce toxic side effects. Future studies will add drugs that target different pathways or different components of the same pathway and other hallmarks of cancer such as metabolic reprogramming and immunity. Additionally, incorporating inhibitors of epigenetic changes linked to malignancies would be of great commercial application.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.